Neu-120

N/A

Report date: 2022/07/04 19:38:02
NME

Base Information

Drug NameNeu-120
Drug Alias NameNeu-120
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlycogen synthase kinase-3 beta inhibitorsMonoamine oxidase B inhibitorsGlutamate [NMDA] receptor modulators
TargetsGlycogen synthase kinase-3 betaMonoamine oxidase BGlutamate [NMDA] receptor
Therapy Area/IndicationsLevodopa-induced dyskinesia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeurim Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeurim Pharmaceuticals Ltd
Active IndicationsN/A
Inactive IndicationsLevodopa-induced dyskinesia

Other Information

ATC CodeN/A
Related LinksN/A